Skip to main content

Table 3 Literature review on linac-based SRS on BSM

From: Stereotactic radiosurgery for the treatment of brainstem metastases: a multicenter retrospective study

Study Population Metastases Median prescription dose (range) Local control Survival (median) Neurological death rate Death by local progression rate Toxicity
Samblàs et al. [28] 28 30 Median 11.1 Gy (5–20) n/a 16.8 months 42.8% 3.5% n/a
Hatiboglu et al. [10] 60 60 Median 15 Gy (8–18) 1-y: 35% 4 months 7% 2% Hemiparesis (6.6%)
Nausea/vomiting (6.6%)
Headache (5%)
Cranial nerve deficit (3%)
Hemorrage (3%)
Kelly et al. [29] 24 24 Median 13 Gy (8–16) 1-y: 78.6% 5.3 months 12.5% 0% Ataxia (4%)
Acute confusion (4%)
Valery et al. [21] 30 43 Median 13.4 Gy (8.2–15) 1-y: 79% 10 months 42% (8 of 19 assessable cases) n/a Headache (13%)
Lin et al. [11] 45 48 Median 14 Gy (10–17) 1-y: 88% 11.6 months n/a n/a Overall: 4.7%
Sugimoto et al. [30] 24 25 24–40 Gy/7–13 fr 96% 9 months n/a 0% Nausea (4%)
Present study 105 111 35.7 Gy10 (23.8–60) 1-y: 90.4% 11 months 24.7% 2.8% Headache (2.8%)
Pseudoprogression (1%)